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Abstract  
Background 
Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG 
repeat in the HTT gene.  It is diagnosed following a standardized exam of motor control and often 
presents with cognitive decline and psychiatric symptoms. Recent studies have detected genetic loci 
modifying the age at onset of motor symptoms in HD, but genetic factors influencing cognitive and 
psychiatric presentations are unknown.   
Methods 
We tested the hypothesis that psychiatric and cognitive symptoms in HD are influenced by the same 
common genetic variation as in the general population by constructing polygenic risk scores from 
large genome-wide association studies of psychiatric and neurodegenerative disorders, and of 
intelligence, and testing for correlation with the presence of psychiatric and cognitive symptoms in a 
large sample (n=5160) of HD patients. 
Results 
Polygenic risk score for major depression was associated specifically with increased risk of 
depression in HD, as was schizophrenia risk score with psychosis and irritability. Cognitive 
impairment and apathy were associated with reduced polygenic risk score for intelligence. 
Conclusions 
 Polygenic risk scores for psychiatric disorders, particularly depression and schizophrenia, are 
associated with increased risk of the corresponding psychiatric symptoms in HD, suggesting a 
common genetic liability. However, the genetic liability to cognitive impairment and apathy appears 
to be distinct from other psychiatric symptoms in HD. No associations were observed between HD 
symptoms and risk scores for other neurodegenerative disorders. These data provide a rationale for 
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treatments effective in depression and schizophrenia to be used to treat depression and psychotic 
symptoms in HD. 
Introduction 
Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG 
repeat in HTT. A clinical diagnosis is typically made via a movement disorder, but nearly all 
participants experience progressive cognitive decline, and many exhibit behavioural and psychiatric 
symptoms (1).  Depression, irritability, obsessive and compulsive symptoms, apathy and psychosis all 
occur at rates higher than seen in the non-HD population, though they are not universal in HD (2).  
Psychiatric symptoms are often present before motor symptoms become manifest. Age at motor 
onset of HD is determined both by the length of the CAG repeat tract in HTT and by other genetic 
variants in the genome (3–5). Despite the fact that age at motor onset measures only one specific 
facet of the pathological process (1), it has been widely used to identify genetic modifiers in HD 
whilst genetic influences on behavioural and neuropsychiatric symptoms in HD have not been 
systematically investigated.  Small studies have shown familial aggregation of psychosis in HD (6,7) 
with weak evidence for the influence of specific candidate genes (8). 
Common genetic variation contributes to the risk of developing schizophrenia (SCZ) (9), bipolar 
disorder (BPD) (10), major depressive disorder (MDD) (11) and attention deficit hyperactivity 
disorder (ADHD) (12).  There is significant shared genetic risk between these psychiatric disorders 
(13). 
 Increased general intelligence (g) – a measure of cognitive function - has been shown to be 
genetically correlated with reduced risk of Alzheimer’s disease (AD), ADHD and schizophrenia (14). 
As in HD, there are substantially increased levels of psychiatric symptoms in many neurological 
diseases. For instance 50% of those with AD (15), and up to 75% of those with Parkinson’s disease 
(PD) develop psychotic symptoms (16,17).  In dementia with Lewy bodies visual hallucinations are a 
core clinical feature seen in 80% of patients (18). AD with psychosis is heritable (19,20), though 
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increasing polygenic risk score for schizophrenia was associated with reduced risk of psychosis in AD 
(21).  
Given the increased frequency of neuropsychiatric and cognitive symptoms in HD, it is of interest to 
test for genetic overlap of these symptoms with psychiatric and neurodegenerative disorders and 
intelligence. This was done by constructing polygenic risk scores using the latest available genome-
wide association studies for these disorders and testing these for correlation with the presence of 
neuropsychiatric and cognitive symptoms in HD.   
Materials & Methods 
HD participants and phenotypes 
The HD participants in this analysis were part of the European REGISTRY study (22) or its successor, 
the international Enroll-HD (23) observational study of HD. REGISTRY was a multisite, prospective, 
observational study, which collected phenotypic data (2003–13) for more than 13000 participants, 
mostly HD gene carriers with manifest disease. Enroll-HD is an expanded and modified version of the 
REGISTRY study and is international: to date it has over 16000 participants (some of whom rolled 
over from REGISTRY) from 19 nations. All experiments were performed in accordance with the 
Declaration of Helsinki, ethical approval for the REGISTRY and Enroll-HD studies including written 
informed consent of all participants was obtained. This study was approved by Cardiff University 
School of Medicine Research Ethics Committee.  
There were 6278 individuals with manifest HD defined by motor onset from REGISTRY (n=4986) and 
Enroll-HD (n=1292) with appropriate quality-controlled genome-wide association study (GWAS) data 
as described in (5). We examined seven symptoms: depression, irritability, psychosis, apathy, 
violent/aggressive behaviour, perseverative/obsessive behaviour and cognitive impairment, from 
the clinical characteristics questionnaire (CCQ) in REGISTRY and Enroll-HD. The clinical characteristics 
questionnaire asks if a sign or symptom has ever been experienced by a subject, (see Supplementary 
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Information). At least one CCQ symptom endorsement (positive or negative) was recorded in 5854 
participants (4563 REGISTRY, 1291 Enroll-HD). We removed 133 individuals with a comorbid 
diagnosis of bipolar disorder, schizophrenia, schizotypy or schizoaffective disorder (since these are 
likely to share risk genes for psychiatric disorders independently of their HD status). We also 
removed one member (561 individuals) of each pair of first or second degree relatives (IBD>0.25) to 
minimise the correlation between individuals due to cryptic relatedness. This left 5160 participants 
in the final analysis (Supplementary Figure 1). 
 
 
Genetic analysis 
For each individual in the HD dataset, their genetic risk for each psychiatric/neurodegenerative 
disorder was captured by a polygenic risk score (PRS) (24).  A PRS is defined as the sum of the 
number of minor alleles across a set of SNPs, each weighted by the corresponding risk of that allele 
for the psychiatric/neurodegenerative disorder observed in a “training” GWAS. The set of SNPs used 
to calculate the PRS was chosen to be present in both the training GWAS and the HD dataset, to be 
in approximate linkage equilibrium, and to capture as much of the association signal in the training 
GWAS as possible. Following the procedure outlined by the Psychiatric Genomics Consortium (9), 
this was achieved by using PLINKv1.9 (25) to select the most significant SNP in the training GWAS, 
removing all SNPs within 500kb that are in linkage disequilibrium (r2>0.1) with it, then moving to the 
next most significant remaining SNP and repeating the process. Analysis was restricted to SNPs with 
minor allele frequency >0.01 that were well imputed (r2 between allele dosages and the unknown 
true genotypes >0.9) in the HD dataset and (where this information was available) in the training 
GWAS.  SNPs were selected for inclusion into the PRS by applying criteria to their p-values in the 
training set. Since the optimal criterion was not known a priori, we applied six different p-value 
cutoffs (p<0.0001, p<0.001, p<0.01, p<0.05, p<0.5, p<1). Effects of population stratification were 
 8 
removed by regressing the PRS on 20 principal components. The residuals from this regression were 
standardised, to enable comparison of effect sizes across cutoffs. 
Nine large publicly available sets of GWAS summary statistics were used for training (Supplementary 
Table 1). These comprised five GWAS of psychiatric disorders from the Psychiatric Genomics 
Consortium (PGC): schizophrenia, bipolar disorder (BPD), attention deficit hyperactivity disorder 
(ADHD), autism spectrum disorder (ASD) and obsessive compulsive disorder (OCD) (9,10,12,26,27), a 
meta-analysis of the PGC and UK Biobank major depressive disorder (MDD) samples (11), two 
neurodegenerative disorders: late-onset Alzheimer’s disease (AD) (28), and Parkinson’s disease (PD) 
(29), and a large GWAS of g, a measure of general intelligence (14). The major histocompatibility 
complex (MHC) region was removed from the schizophrenia GWAS due to a strong schizophrenia 
signal and long-range linkage disequilibrium potentially biasing the PRS (9). Summary statistics for 
the Psychiatric Genomics Consortium GWAS (including the PGC and UK Biobank MDD meta-analysis) 
are available from https://www.med.unc.edu/pgc/results-and-downloads, those for the AD and 
intelligence GWAS from https://www.ebi.ac.uk/gwas/downloads/summary-statistics, and the PD 
GWAS (omitting 23 and Me samples) from https://drive.google.com/drive/folders/10bGj6HfAXgl-
JslpI9ZJIL_JIgZyktxn. 
Associations were tested between all 9 PRS and all 7 symptoms at each PRS cutoff. The following p-
value criteria were used to define significance correcting for multiple testing: 7.94x10-4 (Bonferroni 
corrected for 7 symptoms tested on 9 disease PRS, a total of 63 tests), 1.32x10-4 (Bonferroni 
corrected for 63 tests x 6 PRS cutoffs) 
We also defined 27 PRS-symptom comparisons as primary hypotheses of interest, reflecting prior 
associations in the general population between the phenotypes and the diseases from which the PRS 
were derived. These were:  
• MDD with depression, irritability and apathy 
• BPD with depression and irritability 
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• Schizophrenia with depression, irritability, psychosis, apathy and violent/aggressive 
behaviour 
• ADHD with irritability, violent & aggressive behaviour and cognitive impairment 
• ASD with irritability, psychosis and perseverative/obsessive behaviour 
• OCD with perseverative/obsessive behaviour 
• AD with depression, irritability, apathy, violent/aggressive behaviour and cognitive 
impairment 
• PD with depression, irritability, apathy and cognitive impairment 
• Intelligence with cognitive impairment 
 
Results 
The frequency of each symptom in the 5854 HD participants with at least one endorsed symptom 
(positive or negative) varied from 10.8% (psychosis) to 66.0% (depression), and differed significantly 
by sex for depression, which was more common in women, and irritability and violent/aggressive 
behaviour which were both more common in men (Table 1).  Symptoms were significantly 
(positively) correlated with each other (Supplementary Table 2), resulting in individuals exhibiting 
multiple symptoms.  
We approximated disease duration as the age at the most recent observation available minus age at 
motor onset for REGISTRY and Enroll-HD individuals.  Mean duration of HD was significantly lower in 
Enroll-HD, at 6.54 years, than REGISTRY, at 8.14 years (p=6.55x10-21). The effects of CAG length, age 
at motor onset, sex and disease duration on symptom presence, were tested simultaneously via 
logistic regression (Table 2), along with potential differences in symptom frequency between 
REGISTRY vs Enroll-HD. Increased disease duration was significantly correlated with symptom 
presence for all symptoms except depression. These associations remained significant when age at 
most recent visit was included in the model (to account for increasing frequency of symptoms with 
 10
increasing age) instead of age at motor onset (results not shown). Thus, the increased frequency of 
symptoms with disease duration cannot simply be attributed to age.  Perseverative/obsessive 
behaviour was seen substantially more frequently in Enroll-HD than REGISTRY participants (p = 
5.72x10-10), otherwise there were no significant differences. 
Supplementary Table 3 lists the PRS-symptom associations reaching nominal (p<0.05) significance, 
with only the PRS cutoff giving the most significant result being shown. Full PRS-symptom analyses 
are shown in Supplementary Tables 4-12. The schizophrenia PRS showed significant associations 
with psychosis, irritability and violent and aggressive behaviour after correction for both the number 
of PRS-symptom tests and the six PRS cutoffs, as did the MDD PRS with depression, irritability and 
violent and aggressive behaviour. The associations of schizophrenia PRS with depression and 
perseverative/obsessive behaviour were significant after correction for the number of PRS-symptom 
tests, as was the association between BPD PRS and depression. Of the primary hypotheses, the 
following nominally significant associations were also observed: MDD PRS with apathy, ADHD PRS 
with violent and aggressive behaviour, PD PRS with cognitive impairment and (interestingly, given 
the relatively small training GWAS) OCD PRS with perseverative/obsessive behaviour. In each case, 
increased PRS was associated with an increased risk of the symptom (as shown by odds ratios >1 in 
Supplementary Table 3). Associations of the intelligence PRS with violent and aggressive behaviour, 
apathy and cognitive impairment were significant after correction for both the number of PRS-
symptom tests and the 6 PRS cutoffs, while the association between intelligence PRS and irritability 
was significant after correction for the number of PRS-symptom tests.  The associations with 
intelligence PRS have OR <1 in Table 2, indicating that decreased PRS (i.e. reduced intelligence) is 
associated with increased risk of the symptom.  In general, PRS-symptom associations in 
Supplementary Table 3 surviving correction for multiple testing of symptom-PRS comparisons 
showed at least nominally significant association over a range of PRS cutoffs (Figures 1, 2 and 3, 
Supplementary Tables 4,5,12) thus increasing confidence that these results are robust. Conversely, 
the association between PD PRS and cognitive impairment was only significant for PRS cutoff 
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p<0.0001 (Supplementary Table 11), making it likely that this is a false positive. This is also the case 
for the apparent association between psychosis and AD PRS (Supplementary Table 10).  It can be 
seen from Supplementary Table 3  that the proportion of symptom variance accounted for by the 
PRS, as measured by the Nagelkerke R2, is small (<1%). Likewise, the ability of the PRS to predict 
symptom presence, as measured by the AUC, is limited (AUCs <0.55). For comparison, the 
Psychiatric Genomics Consortium (9) observed that schizophrenia PRS accounted for ~7% of variance 
in schizophrenia liability, with AUC around 0.7.  AUC of 0.8 is generally required for a clinically useful 
predictor (30).  
Since sex, CAG length, age at motor onset and disease duration were found to correlate significantly 
with symptom risk (Table 2), the association analyses between PRS and symptom were repeated 
conditioning on the effects of the factors found to be significantly associated with symptom 
presence. This made little difference to the significance of the PRS-symptom associations 
(Supplementary Table 13). Together, these factors give AUC of 0.57-0.64 (Table 2), and adding the 
PRS makes little difference to this (Supplementary Table 13). 
For symptoms with a significant association with sex (depression, irritability and violent and 
aggressive behaviour) and PRS with a significant association in the whole sample, the PRS-symptom 
association analyses were run in males and females separately (Supplementary Table 14). There 
were no significant differences in OR between males and females. 
 PRS for schizophrenia, MDD, BPD and intelligence are associated with multiple symptoms in 
Supplementary Table 3. Since these symptoms are correlated (Supplementary Table 2), it is unclear 
which symptom is driving the association. Likewise, symptoms are often associated with multiple 
PRS in Supplementary Table 3. These PRS will be correlated, due to genetic overlap between 
psychiatric disorders (13).  We therefore performed logistic regression of each symptom on all the 
significant PRS from Supplementary Table 3 simultaneously, including the six other symptom 
diagnoses as covariates (Table 3). This analysis highlighted specific associations between MDD PRS 
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and depression, schizophrenia PRS and both psychosis and irritability, BPD PRS and 
violent/aggressive behaviour and intelligence PRS and cognitive decline. AD PRS and PD PRS were 
significantly associated with psychosis and cognitive impairment respectively, but these are likely to 
be false positives, as discussed above.  
The number of symptoms seen in any individual can be regarded as a surrogate for disease severity, 
and might be expected to correlate with PRS. A linear regression of PRS on symptom count (0-7) was 
therefore performed, (Supplementary Table 15). Significant associations  with symptom count were 
observed for schizophrenia (p=4.45x10-9), intelligence (p=5.78x10-8), MDD (p=4.17x10-8) and BD 
(p=0.00268), with the latter being attributable to correlation with the other PRS. To test whether 
association of PRS with individual symptoms can be explained by the general association with 
symptom count, the number of other symptoms was included as a covariate in the regression of PRS 
on symptom presence. Psychosis and irritability were found to be associated with schizophrenia PRS 
independently of other symptoms (Supplementary Table 16). Depression was associated with MDD 
PRS across all cutoffs (Supplementary Table 17), as was cognitive impairment with intelligence PRS 
(Supplementary Table 18). These results corroborate the specific PRS-symptom associations from 
the previous paragraph.   
Discussion 
We show significant genetic overlaps between psychiatric disorders and psychiatric symptoms in HD, 
along with genetic overlap between intelligence and cognitive symptoms in HD.  There is little 
overlap between the two neurodegenerative disorders and neuropsychiatric symptoms or cognition 
in HD. While the overall pattern of individual associations is complex, reflecting the genetic 
relationships between the disorders, (see Figure 4 for a graphical overview), we were able to identify 
that MDD PRS is specifically associated with depression, schizophrenia PRS with psychosis and 
irritability, BPD PRS with violent/aggressive behaviour and intelligence PRS with cognitive 
impairment. 
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 Our results are consistent with observations of shared genetic risk amongst psychiatric disorders but 
no overlap of genetic risk between the individual neurological disorders and no overlap of genetic 
risk for neurological disorders with neuropsychiatric symptom risk in neurodegenerative disorders 
(13,21,29). By contrast, common genetic variation is associated with behavioural phenotypes (such 
as autistic behaviour and developmental delay) in severe monogenic neurodevelopmental disorders, 
with similar effect sizes (R2 of 0.6-0.8%) to those observed here (31). These results, along with ours, 
indicate that even in diseases previously assumed to be entirely attributable to single genetic 
variants, there is a contribution of polygenic risk in influencing phenotypic presentation (31). 
Schizophrenia PRS is associated with psychosis (and irritability) independently of other symptoms 
and is the only PRS to predict HD psychosis. While psychosis in HD is around ten times more 
common than in the general population, it is seen in only a minority of cases (2), as in the 
participants studied here (11%). There are also reports of clustering of psychotic symptoms in HD 
families (6,7), implying a genetic contribution to these symptoms. Previously, Tsuang et al. (8) tested 
for association of psychosis in HD with a set of 214 SNPs chosen from candidate genes for 
schizophrenia, HD or psychosis in neurodegenerative disorders. None of their associations survived 
correction for multiple testing, possibly due to the small sample size (47 HD cases with psychosis, 
126 without psychosis). Of the SNPs tested by Tsuang et al., 183 were available in our data; a 
polygenic risk score generated from these (with effect sizes taken from the PGC schizophrenia 
GWAS) showed no association with psychosis in our HD sample (OR=0.97, p=0.536). The highly 
significant association between schizophrenia PRS and psychosis observed in our sample shows the 
benefits of a large sample size of HD patients, along with a larger set of SNPs systematically selected 
for association with schizophrenia in a powerful schizophrenia GWAS. The schizophrenia PRS is also 
the most significantly associated with perseveration, one of the most characteristic behavioural 
problems in HD. The PRS for OCD also influences the presence of perseverative/obsessive behaviour 
(Table 3, Supplementary Table 3), despite the OCD PRS having been derived from a much smaller 
and less powerful sample than that for schizophrenia.   
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Schizophrenia may be regarded as a neurodevelopmental disorder with origins in foetal 
development (32) that manifest in symptoms most usually in early adulthood, whereas psychotic 
symptoms in HD generally manifest later in life (2,33).  Genes expressed in the medium spiny 
neurons (MSNs)  of the striatum are amongst the neuronal subtypes most enriched for 
schizophrenia risk (34). MSNs are the most vulnerable cell types in HD: by the time HD motor 
symptoms are manifest up to half of these neurons have died (35). Susceptibility to psychiatric 
symptoms in surviving cells may therefore be influenced by the schizophrenia polygenic risk, 
providing a hypothesis for the increased rates of psychotic symptoms observed in HD patients.  
Cognitive decline and dementia are part of HD progression, with executive and psychomotor 
function often the first deficits noted, with memory problems later in disease (2). Longer CAG repeat 
tracts are associated with increased risk of cognitive deficits in our sample: the previous data on this 
relationship have been inconsistent (2,36). Recent studies have shown that poorer performance in 
the symbol digit modality test was associated with longer HTT CAG repeat lengths (37), and poorer 
cognitive function was seen with increasing repeat lengths in the disease causing range (38).  The 
clinical characteristics questionnaire used to assess symptoms for this study seeks an integrated 
measure of cognitive decline by asking about problems that might interfere with performing 
everyday functions and is relatively crude, though this will be partly offset by the larger size of our 
study (1000s rather than 100s of participants).  
It is notable that neither apathy nor cognitive dysfunction in HD are correlated with PRS for 
psychiatric or neurodegenerative disorders apart from nominal associations between apathy and 
MDD, schizophrenia and BPD PRS, which become non-significant when accounting for the presence 
of other symptoms (see Table 3). However, both are significantly correlated with a PRS measuring 
intelligence. This suggests that apathy in HD should be considered as a cognitive, rather than 
psychiatric, symptom (unlike depression), and is also consistent with apathy being the only 
psychiatric symptom to correlate with disease progression (39). Higher PRS for intelligence is 
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associated with later cognitive decline in HD, as it is in AD (14). The genes associated with 
intelligence are highly expressed in medium spiny neurons of the striatum and pyramidal neurons of 
the CA1 hippocampus (14), early targets of degeneration in HD and AD respectively, potentially 
contributing to the severe cognitive decline seen in these diseases. Surprisingly, there is no 
significant association between the presence of cognitive deficits in HD and genetic risk for AD, 
though AD PRS predicts memory decline and poorer cognitive performance in healthy children and 
adults well before the age of risk for AD (40,41). In children, HTT CAG repeat length itself shows an 
inverted J-shaped relationship with cognition, with maximum cognition at 40-41 repeats (38). Since 
higher intelligence is associated with better health and increased well-being (42), there may thus be 
a selective advantage of longer HTT CAG repeat length, below the threshold for HD, in the wider 
population.  
Depression is very common in HD and more common in females (2). MDD PRS is specifically 
associated with increased risk of depression in HD (Table 3). However, there were no significant sex 
differences in these associations (Supplementary Table 14). There is a significant correlation in our 
sample of increased likelihood of depression with shorter CAG repeat lengths in the disease-causing 
allele in HTT (Table 2), along with an association with earlier age at motor onset. The reason for 
these associations is unclear; the obvious explanation that longer disease duration makes depression 
more likely is not the case in our sample (Table 2). In fact, the apparent associations between 
depression and both age at motor onset and CAG repeat length are explained by the residual of age 
at motor onset after correction for CAG length (see (5) for how this is derived). Participants with an 
earlier than expected age at onset (given their CAG length) are more likely to have depression. This 
could be due to increased environmental stress among individuals with earlier motor onset, and also 
that some genetic modifiers of age at motor onset may also be associated with depression in HD. 
The few previous studies, each examining less than 100 participants, detected no relationship 
between CAG length and presence of depression (43–45). In the non-disease causing range, longer 
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HTT CAG length from 24 to 38 repeats was associated with an increased likelihood of depression 
(46).  
Irritability, like depression, is very common in HD and has a significantly reduced risk with longer 
CAG length (Table 2) but unlike depression, longer duration of disease makes irritability more likely. 
This association is not explained by increased age. Schizophrenia PRS is associated with increased 
risk of irritability (Table 3, Supplementary Table 3). Violent/aggressive behaviour can be considered 
to be an extreme manifestation of irritability, and is associated with PRS for bipolar disorder (Table 
3), with the apparently more significant associations with schizophrenia, intelligence and MDD PRS 
(Supplementary Table 3) attributable to correlations between violent/aggressive behaviour and 
other symptoms. As in the wider population violence and aggressive behaviour is more common in 
men (2). 
The study presented here has a number of limitations. As noted, the clinical characteristics 
questionnaire is a relatively crude instrument. The larger size of this study compared with previous 
studies partly mitigates its limitations, and these initial findings provide a platform for more detailed 
studies using specific psychiatric instruments. We note that all Enroll-HD participants now undergo a 
short problem behaviours assessment battery (PBA), which may account for the increased frequency 
of perseverative/obsessive behaviour observed in Enroll-HD relative to REGISTRY. It would be useful 
to investigate further the predictive power of the PRS using more detailed clinical data, including age 
at onset, on the psychiatric symptoms in HD. It would also be interesting to explore the overlap of 
multiple symptoms and the psychiatric and cognitive PRS to attempt to establish directions of 
causation. 
It is notable that the PRS for psychiatric diseases associate with increased risk of developing parallel 
phenotypic behavioural and psychiatric symptoms in HD participants. The data available in the 
ongoing Enroll-HD study will provide for a much more detailed analyses of these symptoms, their 
aetiology and treatment and may in turn inform the psychiatric diseases. The lack of genetic overlap 
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with other neurodegenerative disorders, consistent with the Brainstorm study (13), implies different 
underlying pathways leading to degeneration in the different neurodegenerations that may relate to 
the disease-specific characteristic differential neuronal vulnerabilities to degeneration. Striatial 
medium spiny neurons are most vulnerable in HD, dopaminergic neurons of the substantia nigra in 
PD and hippocampal and entorhinal cortical neurons in AD. The differential vulnerability may relate 
to pathways essential to the survival and continued function of each specific cell type and these are 
likely to be different in different neurodegenerations (47). Thus, psychiatric symptoms may be 
mediated by common dysfunctional pathways in surviving cells whereas cognitive and 
neurodegenerative symptoms are likely due to specific regional cellular populations degenerating via 
different pathways. Further study of the relevant genes and pathways may provide a rationale for 
the application of treatments used in the wider population for depression and psychosis to these 
symptoms in HD. 
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Figure Legends 
 
Figure 1. Association of increased schizophrenia PRS with increased HD symptom frequency. 
Numbers in the box correspond to the p-value thresholds used to derive the PRS. Black line 
corresponds to nominally significant association (p=0.05). Green line indicates associations 
significant after Bonferroni correction for 63 PRS-symptom comparisons (9 PRS x 7 symptoms). Blue 
line indicates associations significant after Bonferroni correction for 63 PRS-symptom comparisons 
and 6 PRS cutoffs. Note: Only symptoms with at least one p-value reaching the green line are shown. 
 
Figure 2. Association of increased major depression PRS with increased HD symptom frequency. 
Numbers in the box correspond to the p-value thresholds used to derive the PRS. Black line 
corresponds to nominally significant association (p=0.05). Green line indicates associations 
significant after Bonferroni correction for 63 PRS-symptom comparisons (9 PRS x 7 symptoms). Blue 
line indicates associations significant after Bonferroni correction for 63 PRS-symptom comparisons 
and 6 PRS cutoffs. Note: Only symptoms with at least one p-value reaching the green line are shown. 
 
Figure 3. Association of decreased intelligence PRS with increased HD symptom frequency. 
Numbers in the box correspond to the p-value thresholds used to derive the PRS. Black line 
corresponds to nominally significant association (p=0.05). Green line indicates associations 
significant after Bonferroni correction for 63 PRS-symptom comparisons (9 PRS x 7 symptoms). Blue 
line indicates associations significant after Bonferroni correction for 63 PRS-symptom comparisons 
and 6 PRS cutoffs. Note: Only symptoms with at least one p-value reaching the green line are shown. 
 
Figure 4. Pattern of association between HD symptoms and PRS from psychiatric, 
neurodegenerative and cognitive disorders.  
Panel A: PRS grouped into psychiatric (black), neurodevelopmental (blue), neurodegenerative 
(orange) and cognitive (cyan) disorders. Significant correlations between the PRS associated with HD 
symptoms are shown by blue (positive correlations) and orange (negative correlations) lines, with 
line width proportional to the correlation magnitude.  Solid lines between PRS and symptoms show 
associations significant after correcting for 63 PRS-symptom combinations (9 PRS x 7 symptoms) and 
6 PRS cutoffs (p<1.32x10-4). Dashed lines show associations significant after correcting for 63 PRS-
symptom combinations (p<7.94x10-4). Dotted lines show nominally significant associations (p<0.05) 
in PRS-symptom combinations that were part of the primary analysis. Bold lines show PRS – 
symptom associations that are significant after correcting for other PRS and symptoms ( Table 3) 
Panel B: Heatmap showing correlations between symptoms (numerical values in Supplementary 
Table 2). All correlations are positive, and statistically significant (p<2.2x10-16) 
 
Table 1: HD symptom counts and sex differences in the 5854 individuals with 
at least one recorded  HD symptom diagnosis (positive or negative).  
Symptom 
Freq 
(%) 
Male Female 
OR(F/M) P(F/M) 
+ - + - 
Depression 66.0 1639 1120 2116 816 1.75 
(1.57,1.96) 
<2e-16 
Irritability 60.3 1757 1005 1675 1252 0.77 
(0.69,0.85) 
8.76e-7 
Psychosis 10.8 299 2396 301 2562 0.94 
(0.79,1.12) 
0.485 
Violent/aggressive  
behaviour (VAB) 
31.2 965 1794 802 2107 0.71 
(0.63,0.79) 
1.90e-9 
Apathy 53.8 1484 1291 1581 1344 1.02 
(0.92,1.14) 
0.664 
Perseverative/obsessive 
Behaviour (POB) 
37.5 1048 1713 1076 1833 0.96 
(0.86,1.07) 
0.451 
Cognitive impairment 57.5 1583 1214 1726 1235 1.07 
(0.97,1.19) 
0.194 
 
Freq(%) is the frequency of the symptom among individuals in the sample for whom a diagnosis of 
that symptom was recorded.  +/- refer to the number of individuals of each sex with/without the 
symptom. 
Table 2: Effect of sex, CAG, age at motor onset, disease duration and sample 
collection (ENROLL vs REGISTRY) on HD symptom frequency   
 HD Symptom Sex (F/M) CAG AMO Duration ENR vs REG AUC 
 OR p OR P OR p OR P OR P  
depression 1.77 8.44e-23 0.95 7.64e-5 0.98 6.35e-6 1.01 0.0572 1.09 0.198 0.592 
irritability 0.77 2.36e-6 0.94 1.06e-5 0.98 3.85e-9 1.02 0.000452 1.06 0.361 0.570 
psychosis 0.96 0.684 1.02 0.313 1.01 0.334 1.06 2.77e-14 0.88 0.242 0.599 
VAB 0.70 1.04e-9 1.00 0.863 0.99 7.95e-5 1.04 1.32e-12 0.97 0.630 0.601 
apathy 1.04 0.482 1.02 0.156 1.00 0.900 1.04  9.84e-15 1.06 0.411 0.572 
POB 0.99 0.865 1.02 0.0603 1.00 0.322 1.05 1.28e-19 1.52 5.72e-10 0.586 
Cognitive impairment 1.10 0.0814 1.05 8.75e-5 1.01 0.112 1.10 2.08e-54 0.96 0.540 0.638 
 
AUC represents the area under the curve, and is a measure of the ability of the covariates to jointly 
predict symptom presence.  VAB = violent/aggressive behaviour. POB= perseverative/obsessive 
behaviour. Analysis applied to 5854 individuals with at least one recorded symptom endorsement 
(not necessarily positive). All variables fitted simultaneously. Significant associations shown in bold. 
 
Table 3: Logistic regression of symptom on multiple PRS simultaneously, 
correcting for the other symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptom-PRS pairs included in the analysis if they reach nominal significance (p<0.05) when 
analysed alone. The PRS cutoff giving the most significant association was used. Symptom-PRS pairs 
shown in bold reach nominal significance (p<0.05) after correction both for the other PRS shown in 
the table and for the other symptoms. Primary symptom-PRS hypotheses (see text) are underlined. 
VAB= violent/aggressive behaviour, POB=perserverative/obsessive behaviour. MDD= major 
depressive disorder. BPD= bipolar disorder. ASD= autism spectrum disorder. ADHD = attention 
deficit hyperactivity disorder. OR= Odds ratio for presence of symptom associated with 1 s.d. 
increase in PRS.  
 
 
SYMPTOM PRS PRS CUT-OFF OR P VALUE 
Depression 
 
MDD 
Schizophrenia 
BPD 
Intelligence 
0.01 
0.05 
0.01 
0.001 
1.14 
1.04 
1.07 
0.99 
8.52x10
-5
 
0.253 
0.0617 
0.679 
Irritability Schizophrenia 
MDD 
Intelligence 
0.05 
0.001 
1 
1.09 
1.07 
0.97 
0.0164 
0.117 
0.384 
Psychosis  Schizophrenia 
MDD 
Alzheimer’s 
Intelligence 
0.001 
0.05 
0.001 
0.0001 
1.14 
1.05 
1.13 
0.95 
0.00688 
0.302 
0.0139 
0.296 
VAB Intelligence 0.01 0.93 0.0630 
 Schizophrenia 0.05 1.03 0.480 
 MDD 0.001 1.04 0.272 
 BPD 0.001 1.14 9.11x10
-4
 
 ADHD 0.05 1.05 0.209 
 ASD 0.01 1.04 0.262 
POB Schizophrenia 
BPD 
Intelligence 
MDD 
OCD 
0.01 
0.5 
0.01 
0.5 
0.001 
1.03 
1.06 
       0.97 
1.01 
1.07 
0.446 
0.0725 
0.393 
0.783 
0.0532 
 
 
 
 
Apathy Intelligence 
MDD 
BPD 
Schizophrenia 
ASD 
1 
0.05 
0.001 
0.0001 
0.001 
0.95 
1.00 
1.05 
1.03 
1.06 
0.137 
0.980 
0.110 
0.380 
0.0808 
Cognitive  Intelligence 0.01 0.91 0.00411 
impairment Parkinson's 0.0001 1.10 0.00355 
 MDD 0.5 1.03 0.319 
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Supplementary Figure S1: 
Flow diagram showing how the sample used to test association between PRS 
and symptoms was derived. 
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Supplementary Table S1: Sample sizes of GWAS used as training sets for 
polygenic risk scores. 
DISORDER NUMBER OF CASES NUMBER OF CONTROLS 
Major depressive disorder (MDD) 170,756 329,443 
Bipolar disorder (BPD) 20,352 31,358 
Schizophrenia (SCZ) 36,989 113,075 
Attention deficit hyperactivity disorder (ADHD) 20,183 35,191 
Autism spectrum disorder (ASD) 18,382 27,969 
Obsessive-compulsive disorder (OCD) 2,688 7,037 
Alzheimer's Disease (AD) 17,008 37,154 
Parkinson's Disease (PD) 26,421 442,271 
Intelligence 269,867 individuals  
 
 
Supplementary Table S2: Correlations between symptoms.  
 irb psy VAB cog apt POB 
dep 0.242 0.139 0.184 0.168 0.291 0.161 
irb  0.162 0.466 0.194 0.270 0.303 
psy   0.250 0.165 0.139 0.199 
VAB    0.213 0.234 0.281 
cog     0.300 0.210 
apt      0.278 
 
All correlations highly significant (p<2.2x10-16) 
dep = depression, irb = irritability, psy = psychosis,  VAB = violent/aggressive behaviour. POB= 
perseverative/obsessive behaviour. cog=cognitive impairment, apt=apathy 
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Supplementary Table S3:  Individual HD symptom-polygenic risk score 
associations reaching nominal significance 
SYMPTOM Risk score PRS CUT-OFF OR R2 (%) AUC P VALUE 
Depression 
 
MDD 
Schizophrenia 
BPD 
Intelligence 
0.01 
0.05 
0.01 
0.001 
1.17 
1.12 
1.11 
0.93 
0.78 
0.37 
0.36 
0.18 
0.547 
0.528 
0.532 
0.519 
9.01 x 10-8 
2.47 x 10-4 
3.06 x 10-4 
9.51 x 10-3 
Irritability Schizophrenia 
MDD 
Intelligence 
0.05 
0.001 
1 
1.17 
1.12 
0.90 
0.76 
0.45 
0.37 
0.542 
0.535 
0.531 
1.03 x 10-7 
4.42 x 10-5 
1.99 x 10-4 
Psychosis  Schizophrenia 
MDD 
Alzheimer’s 
Intelligence 
0.001 
0.05 
0.001 
0.0001 
1.20 
1.14 
1.10 
0.90 
0.64 
0.34 
0.19 
0.24 
0.548 
0.537 
0.529 
0.534 
5.98 x 10-5 
3.40 x 10-3 
0.0265 
0.0147 
VAB Intelligence 0.01 0.89 0.50 0.537 2.44 x 10-5 
 Schizophrenia 0.05 1.13 0.46 0.532 5.46 x 10-5 
 MDD 0.001 1.13 0.44 0.536 8.45 x 10-5 
 BPD 0.001 1.11 0.34 0.527 5.35 x 10-4 
 ADHD 0.05 1.09 0.22 0.523 5.26 x 10-3 
 ASD 0.01 1.06 0.11 0.517 0.0451 
POB Schizophrenia 
BPD 
Intelligence 
MDD 
OCD 
0.01 
0.5 
0.01 
0.5 
0.001 
1.12 
1.08 
0.93 
1.07 
1.07 
0.39 
0.18 
0.18 
0.15 
0.15 
0.531 
0.521 
0.521 
0.519 
0.521 
1.47 x 10-4 
9.25 x 10-3 
0.0103 
0.0188 
0.0190 
 
 
 
 
Apathy Intelligence 
MDD 
BPD 
Schizophrenia 
ASD 
1 
0.05 
0.001 
0.0001 
0.001 
0.90 
1.08 
1.07 
1.07 
1.06 
0.41 
0.18 
0.14 
0.13 
0.10 
0.534 
0.521 
0.519 
0.518 
0.516 
9.27 x 10-5 
9.17 x 10-3 
0.0222 
0.0254 
0.0499 
Cognitive  Intelligence 0.01 0.89 0.45 0.535 3.90 x 10-5 
impairment Parkinson's 0.0001 1.09 0.26 0.524 1.67 x 10-3 
 MDD 0.5 1.09 0.23 0.524 3.51 x 10-3 
 
VAB= violent/aggressive behaviour, POB=perserverative/obsessive behaviour. MDD= major 
depressive disorder. BPD= bipolar disorder. ASD= autism spectrum disorder. ADHD = attention 
deficit hyperactivity disorder. R2= Nagelkerke R2. OR= Odds ratio for presence of symptom associated 
with 1 s.d. increase in PRS.  
Results in italics satisfy the Bonferroni corrected p-value cut-off 7.94 x 10-4 (corrected for 63 possible 
PRS-phenotype comparisons), and results in bold satisfy the Bonferroni corrected p-value cut of 1.32 
x 10-4 (corrected for the 63 PRS-symptom comparisons and 6 PRS cut-offs). Primary symptom-PRS 
hypotheses (see text) are underlined. 
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Supplementary Table S4: All PRS-symptom analyses for SCZ PRS (no MHC) 
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 1.07(1.01,1.14) 1.08(1.02,1.15) 1.10(1.04,1.17) 1.12(1.05,1.18) 1.10(1.04,1.17) 1.10(1.04,1.17) 
R2 0.0015 0.0020 0.0030 0.0037 0.0029 0.0029 
p 0.0193 0.00715 0.000929 0.000247 0.00114 0.00115 
        
irb OR 1.09(1.03,1.16) 1.11(1.05,1.17) 1.16(1.09,1.22) 1.17(1.10,1.24) 1.15(1.09,1.22) 1.15(1.08,1.21) 
R2 0.0025 0.0035 0.0067 0.0076 0.0061 0.0060 
p 0.00213 0.000318 5.60e-7 1.03e-7 1.82e-6 2.31e-6 
        
psy OR 1.18(1.09,1.29) 1.20(1.10,1.31) 1.19(1.09,1.30) 1.17(1.08,1.28) 1.18(1.08,1.29) 1.17(1.08,1.28) 
R2 0.0057 0.0064 0.0060 0.0051 0.0053 0.0051 
p 0.000148 5.98e-5 0.000103 0.000342 0.000260 0.000350 
        
apt OR 1.07(1.01,1.13) 1.05(0.99,1.11) 1.06(1.00,1.12) 1.05(0.99,1.11) 1.03(0.98,1.09) 1.03(0.98,1.09) 
R2 0.0013 0.0008 0.0010 0.0007 0.0004 0.0004 
p 0.0254 0.0858 0.0549 0.0936 0.231 0.245 
        
VAB OR 1.05(0.99,1.12) 1.05(0.99,1.12) 1.11(1.05,1.18) 1.13(1.07,1.20) 1.11(1.04,1.18) 1.11(1.04,1.18) 
R2 0.0008 0.0008 0.0035 0.0046 0.0032 0.0032 
p 0.0927 0.0892 0.000432 5.46e-5 0.000807 0.000750 
        
POB OR 1.08(1.02,1.14) 1.11(1.05,1.18) 1.12(1.06,1.18) 1.10(1.04,1.16) 1.12(1.05,1.18) 1.12(1.05,1.18) 
R2 0.0019 0.0037 0.0039 0.0027 0.0037 0.0038 
p 0.00799 0.000246 0.000147 0.00161 0.000215 0.000208 
        
cog OR 1.01(0.95,1.07) 1.03(0.97,1.08) 1.05(1.00,1.11) 1.06(1.00,1.12) 1.04(0.98,1.10) 1.04(0.98,1.10) 
R2 2.87e-5 0.0002 0.0009 0.0009 0.0005 0.0005 
p 0.742 0.384 0.0678 0.0592 0.164 0.152 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S5: All PRS-symptom analyses for MDD PRS 
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 1.11(1.05,1.18) 1.13(1.06,1.19) 1.17(1.11,1.24) 1.16(1.09,1.22) 1.15(1.08,1.22) 1.15(1.09,1.22) 
R2 0.0035 0.0045 0.0078 0.0064 0.0058 0.0061 
p 0.000339 5.04e-5 9.01e-8 1.14e-6 3.97e-6 2.34e-6 
        
irb OR 1.12(1.06,1.18) 1.12(1.06,1.19) 1.12(1.06,1.19) 1.11(1.05,1.17) 1.10(1.04,1.16) 1.10(1.04,1.16) 
R2 0.0041 0.0045 0.0043 0.0036 0.0029 0.0030 
p 9.85e-5 4.42e-5 6.67e-5 0.000274 0.000985 0.000823 
        
psy OR 1.08(0.99,1.18) 1.13(1.03,1.23) 1.13(1.03,1.23) 1.14(1.04,1.24) 1.12(1.03,1.22) 1.11(1.02,1.21) 
R2 0.0012 0.0028 0.0029 0.0034 0.0026 0.0022 
p 0.0785 0.00744 0.00655 0.00340 0.0109 0.0162 
        
apt OR 1.02(0.96,1.07) 1.04(0.98,1.10) 1.06(1.00,1.12) 1.08(1.02,1.14) 1.07(1.01,1.13) 1.07(1.01,1.13) 
R2 7.81e-5 0.0005 0.0012 0.0018 0.0016 0.0016 
p 0.588 0.160 0.0356 0.00917 0.0157 0.0149 
        
VAB OR 1.09(1.03,1.16) 1.13(1.06,1.20) 1.13(1.06,1.20) 1.11(1.05,1.18) 1.12(1.06,1.19) 1.12(1.06,1.19) 
R2 0.0023 0.0044 0.0042 0.0033 0.0039 0.0040 
p 0.00379 8.45e-5 0.000116 0.000652 0.000189 0.000183 
        
POB OR 1.00(0.95,1.06) 1.02(0.97,1.08) 1.05(0.99,1.11) 1.06(1.00,1.12) 1.07(1.01,1.13) 1.07(1.01,1.13) 
R2 7.51e-6 0.0002 0.0007 0.0010 0.0015 0.0013 
p 0.868 0.400 0.106 0.0570 0.0188 0.0275 
        
cog OR 1.02(0.96,1.07) 1.07(1.01,1.13) 1.05(0.99,1.11) 1.09(1.03,1.15) 1.09(1.03,1.15) 1.08(1.02,1.14) 
R2 8.72e-5 0.0015 0.0008 0.0023 0.0023 0.0020 
p 0.566 0.0167 0.0777 0.00354 0.00351 0.00546 
 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S6: All PRS-symptom analyses for BPD PRS  
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 1.04(0.98,1.10) 1.07(1.00,1.13) 1.11(1.05,1.18) 1.11(1.05,1.18) 1.07(1.01,1.14) 1.07(1.01,1.14) 
R2 0.0005 0.0012 0.0036 0.0034 0.0016 0.0016 
p 0.198 0.0336 0.000306 0.000466 0.0161 0.0170 
        
irb OR 1.04(0.99,1.10) 1.04(0.98,1.10) 1.04(0.98,1.10) 1.01(0.96,1.07) 1.01(0.96,1.07) 1.01(0.96,1.07) 
R2 0.0006 0.0006 0.0005 4.20e-5 4.24e-5 4.11e-5 
p 0.138 0.150 0.161 0.692 0.691 0.695 
        
psy OR 1.00(0.91,1.09) 1.02(0.94,1.12) 1.05(0.97,1.15) 1.06(0.97,1.15) 1.05(0.96,1.15) 1.07(0.98,1.17) 
R2 1.72e-6 0.0001 0.0006 0.0006 0.0005 0.0009 
p 0.947 0.615 0.236 0.212 0.258 0.141 
        
apt OR 1.05(0.99,1.11) 1.07(1.01,1.13) 1.04(0.98,1.10) 1.00(0.94,1.05) 0.97(0.92,1.03) 0.98(0.92,1.03) 
R2 0.0006 0.0014 0.0005 3.44e-6 0.0002 0.0002 
p 0.120 0.0222 0.185 0.909 0.358 0.436 
        
VAB OR 1.06(1.00,1.13) 1.11(1.05,1.18) 1.08(1.01,1.14) 1.07(1.01,1.14) 1.08(1.01,1.14) 1.08(1.02,1.15) 
R2 0.0012 0.0034 0.0017 0.0014 0.0016 0.0019 
p 0.0413 0.000535 0.0152 0.0245 0.0175 0.00975 
        
POB OR 1.05(0.99,1.11) 1.05(0.99,1.11) 1.06(1.00,1.12) 1.07(1.01,1.13) 1.08(1.02,1.14) 1.08(1.02,1.14) 
R2 0.0008 0.0007 0.0010 0.0014 0.0018 0.0018 
p 0.0839 0.118 0.0553 0.0254 0.00925 0.0113 
        
cog OR 0.98(0.92,1.03) 1.00(0.95,1.06) 1.02(0.97,1.08) 1.03(0.97,1.09) 1.03(0.98,1.09) 1.03(0.97,1.09) 
R2 0.0002 3.76e-7 0.0002 0.0003 0.0003 0.0003 
p 0.421 0.970 0.451 0.305 0.275 0.323 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S7: All PRS-symptom analyses for ADHD PRS 
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 1.00(0.94,1.06) 1.03(0.97,1.09) 1.02(0.96,1.08) 1.02(0.96,1.08) 1.03(0.97,1.09) 1.03(0.97,1.09) 
R2 2.07e-7 0.0002 0.0001 0.0001 0.0002 0.0002 
p 0.978 0.355 0.544 0.473 0.353 0.368 
        
irb OR 0.99(0.94,1.05) 1.02(0.96,1.08) 1.04(0.98,1.10) 1.05(1.00,1.11) 1.05(0.99,1.11) 1.04(0.99,1.10) 
R2 2.88e-5 0.0001 0.0005 0.0009 0.0007 0.0006 
p 0.743 0.518 0.189 0.0741 0.100 0.135 
        
psy OR 1.00(0.91,1.09) 1.04(0.95,1.13) 0.98(0.90,1.07) 1.05(0.96,1.14) 1.07(0.98,1.16) 1.06(0.97,1.16) 
R2 1.94e-6 0.0003 9.51e-5 0.0004 0.0009 0.0007 
p 0.944 0.369 0.624 0.302 0.135 0.173 
        
apt OR 0.99(0.94,1.05) 1.01(0.96,1.07) 1.03(0.97,1.09) 1.03(0,98,1.09) 1.02(0.97,1.08) 1.02(0.97,1.08) 
R2 2.70e-5 4.40e-5 0.0003 0.0004 0.0002 0.0001 
p 0.750 0.684 0.324 0.239 0.432 0.477 
        
VAB OR 1.01(0.95,1.07) 1.02(0.96,1.08) 1.04(0.98,1.10) 1.09(1.03,1.15) 1.08(1.02,1.15) 1.07(1.01.1.14) 
R2 3.97e-5 8.54e-5 0.0004 0.0022 0.0018 0.0016 
p 0.707 0.582 0.225 0.00526 0.0108 0.0179 
        
POB OR 1.01(0.95,1.07) 0.98(0.93,1.04) 1.01(0.96,1.07) 1.00(0.95,1.06) 0.99(0.94,1.05) 0.98(0.93,1.04) 
R2 3.06e-5 0.0001 4.73e-5 3.64e-6 3.31e-5 0.0001 
p 0.738 0.525 0.677 0.908 0.728 0.478 
        
cog OR 0.97(0.92,1.03) 0.99(0.93,1.04) 1.03(0.98,1.09) 1.02(0.97,1.08) 1.05(1.00,1.11) 1.05(1.00,1.11) 
R2 0.0003 6.09e-5 0.0004 0.0002 0.0010 0.0009 
p 0.324 0.632 0.237 0.414 0.0582 0.0691 
 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S8: All PRS-symptom analyses for ASD PRS  
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 0.98(0.92,1.04) 0.98(0.93,1.04) 0.99(0.93,1.05) 0.99(0.93,1.05) 0.97(0.92,1.03) 0.97(0.92,1.03) 
R2 0.0002 8.62e-5 6.29e-5 3.78e-5 0.0003 0.0003 
p 0.446 0.574 0.631 0.710 0.304 0.291 
        
irb OR 1.00(0.94,1.05) 1.03(0.97,1.08) 1.01(0.95,1.07) 1.00(0.95,1.06) 1.00(0.95,1.06) 0.99(0.94,1.05) 
R2 6.72e-5 0.0002 1.72e-5 6.84e-8 8.63e-8 2.58e-5 
p 0.874 0.383 0.800 0.987 0.986 0.756 
        
psy OR 1.02(0.93,1.11) 1.04(0.95,1.13) 1.06(0.97,1.16) 1.04(0.95,1.13) 1.05(0.96,1.14) 1.06(0.97,1.16) 
R2 7.18e-5 0.0003 0.0008 0.0002 0.0004 0.0007 
p 0.670 0.396 0.168 0.434 0.300 0.184 
        
apt OR 1.03(0.97,1.09) 1.06(1.00,1.12) 1.03(0.97,1.08) 1.01(0.96,1.07) 1.00(0.94,1.05) 0.99(0.94,1.05) 
R2 0.0003 0.0010 0.0002 4.65e-5 8.93e-6 1.91e-5 
p 0.328 0.0499 0.345 0.676 0.855 0.789 
        
VAB OR 1.01(0.95,1.07) 1.06(1.00,1.12) 1.06(1,00,1.13) 1.03(0.98,1.10) 1.03(0.97,1.09) 1.03(0.97,1.09) 
R2 4.77e-5 0.0010 0.0011 0.0004 0.0002 0.0002 
p 0.681 0.0603 0.0451 0.255 0.379 0.366 
        
POB OR 0.96(0.91,1.02) 1.04(0.98,1.10) 1.02(0.97,1.08) 1.01(0.96,1.07) 1.01(0.96,1.07) 1.01(0.95,1.07) 
R2 0.0005 0.0004 0.0002 5.43e-5 5.67e-5 3.24e-5 
p 0.159 0.219 0.397 0.656 0.648 0.730 
        
cog OR 0.99(0.94,1.05) 1.05(1.00,1.11) 1.03(0.98,1.09) 1.03(0.98,1.09) 1.00(0.94,1.05) 1.00(0.94,1.05) 
R2 1.79e-5 0.0009 0.0003 0.0004 5.33e-6 1.40e-6 
p 0.795 0.0694 0.266 0.241 0.887 0.942 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S9: All PRS-symptom analyses for OCD PRS  
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 1.04(0.98,1.10) 1.00(0.95,1.06) 1.09(1.03,1.15) 1.07(1.01,1.14) 1.08(1.01,1.14) 1.08(1.02,1.14) 
R2 0.0005 6.39e-6 0.0021 0.0016 0.0016 0.0017 
p 0.170 0.878 0.00516 0.0157 0.0142 0.0129 
        
Irb OR 1.02(0.96,1.08) 1.03(0.98,1.09) 1.02(0.96,1.08) 1.01(0.96,1.07) 1.03(0.97,1.09) 1.02(0.97,1.08) 
R2 9.30e-5 0.0004 0.0001 5.42e-5 0.0002 0.0002 
p 0.556 0.237 0.478 0.653 0.380 0.416 
        
psy OR 1.07(0.98,1.16) 0.98(0.90,1.07) 1.05(0.96,1.15) 0.99(0.91,1.08) 1.00(0.91,1.09) 1.00(0.91,1.09) 
R2 0.0009 7.44e-5 0.0005 2.50e-5 5.20e-6 1.09e-6 
p 0.137 0.665 0.284 0.802 0.909 0.958 
        
apt OR 1.01(0.96,1.07) 1.03(0.98,1.09) 0.99(0.94,1.05) 0.99(0.93,1.04) 1.00(0.95,1.06) 1.00(0.94,1.06) 
R2 7.20e-5 0.0004 1.13e-5 6.54e-5 1.60e-7 8.52e-7 
p 0.603 0.251 0.837 0.620 0.980 0.955 
        
VAB OR 1.02(0.96,1.08) 1.01(0.95,1.07) 1.03(0.97,1.10) 1.01(0.95,1.07) 1.01(0.95,1.07) 1.01(0.95,1.07) 
R2 0.0001 3.73e-5 0.0003 3.79e-5 2.50e-5 2.00e-5 
p 0.498 0.716 0.298 0.714 0.766 0.790 
        
POB OR 1.02(0.96,1.08) 1.07(1.01,1.13) 1.06(1.00,1.12) 1.05(0.99,1.11) 1.07(1.01,1.14) 1.07(1.01,1.13) 
R2 0.0001 0.0015 0.0009 0.0006 0.0015 0.0013 
p 0.515 0.0190 0.0667 0.126 0.0194 0.0281 
        
cog OR 1.00(0.95,1.06) 1.03(0.97,1.09) 1.01(0.96,1.07) 1.00(0.95,1.06) 1.00(0.95,1.06) 1.00(0.95,1.06) 
R2 4.78e-9 0.0003 4.94e-5 5.80e-6 7.45e-6 4.51e-6 
p 0.997 0.298 0.666 0.882 0.867 0.896 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S10: All PRS-symptom analyses for AD PRS  
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 0.97(0.92,1.03) 0.98(0.92,1.03) 0.95(0.91,1.02) 0.98(0.93,1.04) 1.01(0.96,1.07) 1.02(0.96,1.08) 
R2 0.0003 0.0002 0.0005 8.41e-5 4.77e-5 0.0001 
p 0.303 0.427 0.171 0.579 0.676 0.490 
        
irb OR 1.00(0.95,1.06) 1.01(0.95,1.06) 0.99(0.93,1.04) 1.00(0.94,1.05) 1.03(0.97,1.09) 1.03(0.97,1.09) 
R2 7.63e-6 1.00e-5 7.27e-5 5.57e-6 0.0003 0.0002 
p 0.866 0.847 0.602 0.885 0.316 0.346 
        
psy OR 1.05(0.97,1.15) 1.10(1.01,1.20) 1.08(0.99,1.18) 1.06(0.97,1.16) 1.04(0.96,1.14) 1.04(0.96,1.14) 
R2 0.0006 0.0019 0.0013 0.0007 0.0003 0.0004 
p 0.234 0.0265 0.0729 0.181 0.350 0.326 
        
apt OR 1.00(0.94,1.05) 0.97(0.92,1.03) 0.99(0.93,1.04) 1.01(0.95,1.07) 1.03(0.98,1.09) 1.03(0.98,1.09) 
R2 5.56e-6 0.0003 6.26e-5 2.35e-5 0.0003 0.0003 
p 0.885 0.290 0.627 0.766 0.272 0.279 
        
VAB OR 1.00(0.94,1.06) 1.00(0.94,1.06) 1.01(0.95,1.07) 1.03(0.97,1.09) 1.02(0.97,1.09) 1.03(0.97,1.09) 
R2 3.17e-6 7.47e-6 1.56e-5 0.0003 0.0002 0.0002 
p 0.916 0.871 0.814 0.316 0.429 0.393 
        
POB OR 1.00(0.95,1.06) 1.04(0.98,1.10) 1.05(0.99,1.11) 1.05(0.99,1.11) 1.05(0.99,1.11) 1.04(0.99,1.11) 
R2 1.73e-6 0.0005 0.0007 0.0007 0.0008 0.0006 
p 0.937 0.165 0.114 0.119 0.0922 0.143 
        
cog OR 1.00(0.95,1.06) 1.02(0.96,1.08) 0.99(0.93,1.04) 1.00(0.94,1.05) 1.00(0.95,1.06) 1.01(0.95,1.07) 
R2 1.31e-7 0.0001 5.00e-5 8.62e-6 1.68e-6 2.89e-5 
p 0.982 0.503 0.664 0.857 0.937 0.741 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S11: All PRS-symptom analyses for PD PRS 
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 0.99(0.94,1.05) 0.95(0.89,1.00) 0.96(0.91,1.02) 0.97(0.91,1.03) 1.00(0.94,1.06) 1.00(0.94,1.06) 
R2 1.60e-5 0.0009 0.0005 0.0003 4.90e-6 3.87e-6 
P 0.809 0.0620 0.169 0.287 0.893 0.905 
        
irb OR 1.02(0.97,1.08) 0.99(0.93,1.04) 0.99(0.94,1.05) 0.97(0.92,1.03) 0.98(0.93,1.04) 0.98(0.93,1.04) 
R2 0.0002 5.73e-5 2.24e-5 0.0002 0.0001 9.03e-5 
p 0.403 0.643 0.772 0.338 0.521 0.561 
        
psy OR 1.01(0.92,1.10) 0.94(0.87,1.03) 1.01(0.92,1.10) 1.01(0.93,1.10) 1.08(0.99,1.18) 1.08(0.99,1.18) 
R2 1.15e-5 0.0006 1.51e-5 1.78e-5 0.0011 0.0011 
p 0.865 0.203 0.845 0.832 0.0909 0.0960 
        
apt OR 1.01(0.96,1.07) 0.96(0.90,1.01) 0.99(0.93,1.04) 1.01(0.95,1.06) 0.99(0.93,1.04) 0.98(0.93,1.04) 
R2 2.83e-5 0.0007 6.36e-5 9.47e-6 5.47e-5 8.16e-5 
p 0.744 0.108 0.625 0.850 0.650 0.580 
        
VAB OR 1.05(0.99,1.12) 1.00(0.94,1.06) 0.99(0.93,1.05) 0.98(0.92,1.04) 0.98(0.93,1.04) 0.98(0.93,1.05) 
R2 0.0009 2.39e-6 5.05e-5 0.0002 8.71e-5 7.62e-5 
p 0.0798 0.927 0.672 0.419 0.578 0.603 
        
POB OR 1.03(0.98,1.09) 0.96(0.91,1.02) 1.00(0.95,1.06) 0.97(0.92,1.03) 0.98(0.93,1.04) 0.98(0.92,1.04) 
R2 0.0004 0.0006 7.50e-6 0.0002 0.0001 0.0002 
p 0.246 0.155 0.868 0.366 0.507 0.446 
        
cog OR 1.09(1.03,1.16) 1.02(0.96,1.08) 1.04(0.99,1.10) 1.01(0.96,1.07) 0.99(0.94,1.05) 0.99(0.93,1.04) 
R2 0.0026 0.0001 0.0006 5.40e-5 1.78e-5 5.59e-5 
p 0.00167 0.537 0.137 0.652 0.795 0.646 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S12: All PRS-symptom analyses for intelligence PRS 
 
Symptom Statistic PRS cutoff 
0.0001 0.001 0.01 0.05 0.5 1 
        
dep OR 0.95(0.90,1.01) 0.93(0.87,0.98) 0.95(0.89,1.00) 0.94(0.89,1.00) 0.93(0.88,0.99) 0.93(0.88,0.99) 
R2 0.0008 0.0018 0.0010 0.0011 0.0016 0.0016 
P 0.0799 0.00951 0.0593 0.0410 0.0152 0.0166 
        
irb OR 0.92(0.87,0.97) 0.93(0.88,0.99) 0.91(0.86,0.96) 0.90(0.85,0.95) 0.90(0.85,0.95) 0.90(0.85,0.95) 
R2 0.0024 0.0016 0.0032 0.0034 0.0036 0.0037 
p 0.00306 0.0139 0.000532 0.000344 0.000246 0.000199 
        
psy OR 0.90(0.82,0.98) 0.93(0.85,1.01) 0.94(0.86,1.02) 0.95(0.87,1.04) 0.91(0.84,1.00) 0.91(0.84,0.99) 
R2 0.0024 0.0010 0.0008 0.0004 0.0017 0.0017 
p 0.0147 0.104 0.159 0.295 0.0405 0.0371 
        
apt OR 0.94(0.89,1.00) 0.94(0.88,0.99) 0.93(0.88,0.98) 0.91(0.86,0.96) 0.90(0.85,0.95) 0.90(0.85,0.95) 
R2 0.0012 0.0015 0.0020 0.0030 0.0039 0.0041 
p 0.0341 0.0166 0.00650 0.000852 0.000118 9.27e-5 
        
VAB OR 0.91(0.86,0.97) 0.90(0.85,0.96) 0.88(0.83,0.93) 0.89(0.84,0.95) 0.88(0.83,0.93) 0.88(0.83,0.93) 
R2 0.0027 0.0031 0.0050 0.0040 0.0048 0.0048 
p 0.00198 0.00101 2.44e-5 0.000156 4.09e-5 3.94e-5 
        
POB OR 0.96(0.91,1.02) 0.96(0.91,1.02) 0.93(0.88,0.98) 0.93(0.88,0.99) 0.94(0.89,1.00) 0.94(0.88,0.99) 
R2 0.0006 0.0006 0.0018 0.0016 0.0013 0.0014 
p 0.150 0.152 0.0103 0.0149 0.0318 0.0247 
        
cog OR 0.92(0.87,0.97) 0.91(0.86,0.96) 0.89(0.84,0.94) 0.90(0.85,0.95) 0.90(0.85,0.96) 0.90(0.85,0.96) 
R2 0.0025 0.0031 0.0045 0.0040 0.0034 0.0033 
p 0.00213 0.000633 3.90e-5 0.000108 0.000378 0.000384 
 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S13:  HD symptom – polygenic risk score associations 
correcting for significant clinical covariates 
 
VAB= violent/aggressive behaviour, POB=perserverative/obsessive behaviour. MDD= major 
depressive disorder. BPD= bipolar disorder. ASD= autism spectrum disorder. ADHD = attention 
deficit hyperactivity disorder.  Analyses include the covariates significantly associated with each 
symptom in Table 2.  R2= Nagelkerke R2 attributable solely to the PRS . OR= Odds ratio for presence 
of symptom associated with 1 s.d. increase in PRS. AUC refers to the combined prediction of 
covariates and PRS. 
 
 
 
SYMPTOM Risk score PRS CUT-OFF OR R2 (%) AUC P VALUE 
Depression 
 
MDD 
Schizophrenia 
BPD 
Intelligence 
0.01 
0.05 
0.01 
0.001 
1.17 
1.12 
1.11 
0.94 
0.73 
0.37 
0.31 
0.13 
0.600 
0.595 
0.593 
0.591 
2.17x 10-7 
2.30 x 10-4 
6.84 x 10-4 
0.0286 
Irritability Schizophrenia 
MDD 
Intelligence 
0.05 
0.001 
1 
1.16 
1.12 
0.91 
0.70 
0.39 
0.30 
0.583 
0.579 
0.577 
4.64 x 10-7 
1.68 x 10-4 
9.67 x 10-4 
Psychosis  Schizophrenia 
MDD 
Alzheimer’s 
Intelligence 
0.001 
0.05 
0.001 
0.0001 
1.18 
1.13 
1.11 
0.91 
0.55 
0.30 
0.24 
0.19 
0.604 
0.602 
0.598 
0.600 
2.40 x 10-4 
6.80 x 10-3 
0.0164 
0.0297 
VAB Intelligence 0.01 0.88 0.45 0.608 7.17 x 10-5 
 Schizophrenia 0.05 1.14 0.48 0.608 4.22 x 10-5 
 MDD 0.001 1.11 0.33 0.607 6.74 x 10-4 
 BPD 0.001 1.11 0.32 0.605 8.61 x 10-4 
 ADHD 0.05 1.09 0.22 0.604 5.70 x 10-3 
 ASD 0.01 1.06 0.08 0.603 0.0851 
POB Schizophrenia 
BPD 
Intelligence 
MDD 
OCD 
0.01 
0.5 
0.01 
0.5 
0.001 
1.11 
1.07 
0.93 
1.07 
1.08 
0.36 
0.14 
0.18 
0.12 
0.18 
0.583 
0.582 
0.582 
0.580 
0.580 
3.13 x 10-4 
0.0262 
0.0100 
0.0329 
0.0111 
 
 
 
 
Apathy Intelligence 
MDD 
BPD 
Schizophrenia 
ASD 
1 
0.05 
0.001 
0.0001 
0.001 
0.90 
1.08 
1.07 
1.07 
1.05 
0.38 
0.18 
0.14 
0.16 
0.07 
0.576 
0.575 
0.574 
0.575 
0.575 
1.99 x 10-4 
0.0103 
0.0245 
0.0145 
0.0977 
Cognitive  Intelligence 0.01 0.89 0.41 0.636 7.39 x 10-5 
impairment Parkinson's 0.0001 1.10 0.25 0.633 2.19 x 10-3 
 MDD 0.5 1.09 0.24 0.634 2.41 x 10-3 
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Supplementary Table S14: Testing for sex differences in PRS odds ratios for 
symptoms with both a significant sex difference and a significant PRS 
association 
Symptom PRS cutoff All Males Females M vs F 
 P value OR p OR p OR P 
depression SCZ 0.05 1.12 2.47e-4 1.16 3.79e-4 1.08 0.0894 0.207 
 BPD 0.01 1.11 3.06e-4 1.17 1.96e-4 1.06 0.180 0.114 
 MDD 0.01 1.17 9.01e-8 1.18 4.14e-5 1.13 3.51e-3 0.386 
 INT 0.001 0.93 9.51e-3 0.92 0.0342 0.94 0.135 0.719 
          
irritability SCZ 0.05 1.17 1.03e-7 1.15 1.44e-3 1.18 2.74e-5 0.598 
 MDD 0.001 1.12 4.42e-5 1.13 4.19e-3 1.12 6.18e-3 0.869 
 INT 1 0.90 1.99e-4 0.93 0.0966 0.87 3.42e-4 0.202 
          
VAB SCZ 0.05 1.13 5.46e-5 1.14 3.49e-3 1.13 6.59e-3 0.904 
 BPD 0.001 1.11 5.35e-4 1.07 0.0961 1.16 7.73e-4 0.203 
 ADHD 0.05 1.09 5.26e-3 1.08 0.0711 1.12 0.0131 0.588 
 MDD 0.001 1.13 8.45e-5 1.10 0.0243 1.15 1.41e-3 0.436 
 INT 0.01 0.88 2.44e-5 0.88 2.22e-3 0.88 4.08e-3 0.999 
 
VAB = violent/aggressive behaviour.  
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Supplementary Table S15: Association of PRS with number of symptoms 
PRS 
Number of symptoms 
P(fac) P(quant) 0 
(473) 
1 
(700) 
2 
(858) 
3 
(952) 
4 
(865) 
5 
(715) 
6 
(433) 
7 
(164) 
SCZ-0001 -0.090 -0.076 -0.024 0.002 0.051 -0.010 0.142 0.118 0.00285 4.80e-5 
SCZ-001 -0.091 -0.076 -0.027 -0.002 0.039 0.024 0.162 0.109 0.00134 6.48e-6 
SCZ-01 -0.114 -0.094 -0.064 0.024 0.018 0.083 0.167 0.138 5.62e-6 5.06e-9 
SCZ-05 -0.128 -0.076 -0.068 0.023 0.026 0.069 0.164 0.166 5.88e-6 4.45e-9 
SCZ-5 -0.108 -0.068 -0.064 0.036 0.003 0.070 0.132 0.206 4.62e-5 1.11e-7 
SCZ-1 -0.112 -0.069 -0.059 0.032 0.005 0.069 0.128 0.024 6.67e-5 1.25e-7 
BIP-0001 -0.039 -0.069 0.001 -0.004 0.047 -0.014 0.065 -0.021 0.327 0.067 
BIP-001 -0.071 -0.066 -0.024 0.024 0.042 0.005 0.090 0.026 0.109 0.00345 
BIP-01 -0.091 -0.053 -0.020 0.039 0.012 0.024 0.092 0.032 0.102 0.00268 
BIP-05 -0.086 -0.035 -0.002 0.028 -0.011 0.016 0.069 0.101 0.250 0.0118 
BIP-5 -0.067 -0.030 0.008 -0.005 -0.032 0.034 0.047 0.107 0.396 0.0348 
BIP-1 -0.061 -0.029 0.0002 -0.011 -0.033 0.040 0.044 0.120 0.354 0.0273 
MDD-0001 -0.127 -0.082 -0.003 0.032 -0.010 0.067 -0.006 0.102 0.0122 0.000897 
MDD-001 -0.178 -0.069 -0.014 0.052 -0.008 0.081 0.031 0.192 4.32e-5 2.583e-6 
MDD-01 -0.167 -0.074 -0.015 -0.004 0.034 0.059 0.053 0.261 2.46e-5 1.34e-7 
MDD-05 -0.175 -0.082 -0.023 -0.014 0.013 0.067 0.084 0.206 3.25e-5 4.58e-8 
MDD-5 -0.133 -0.117 -0.011 -0.013 0.023 0.058 0.077 0.263 1.34e-5 4.17e-8 
MDD-1 -0.136 -0.116 -0.011 -0.011 0.024 0.057 0.072 0.253 2.15e-5 6.35e-8 
ADHD-0001 -0.030 0.016 0.012 -0.002 0.022 -0.034 -0.022 0.020 0.945 0.800 
ADHD-001 -0.024 0.000 0.005 -0.024 0.034 0.004 -0.033 0.076 0.867 0.602 
ADHD-01 -0.059 -0.039 0.006 0.008 0.030 0.017 0.015 -0.046 0.762 0.203 
ADHD-05 -0.061 -0.043 0.008 -0.020 0.039 0.002 0.038 0.049 0.580 0.0561 
ADHD-5 -0.056 -0.032 -0.014 -0.034 0.079 0.002 0.040 0.020 0.235 0.0464 
ADHD-1 -0.055 -0.029 -0.009 -0.035 0.083 -0.002 0.028 0.009 0.238 0.0821 
ASD-0001 -0.026 0.089 -0.040 -0.010 -0.014 -0.001 -0.069 0.123 0.104 0.586 
ASD-001 -0.004 0.040 -0.041 -0.043 -0.021 0.079 0.052 0.120 0.101 0.102 
ASD-01 -0.015 0.024 -0.045 -0.022 -0.013 0.055 0.048 -0.025 0.547 0.301 
ASD-05 -0.002 0.015 -0.024 -0.074 -0.004 0.045 0.025 0.004 0.426 0.470 
ASD-5 0.041 0.010 -0.034 -0.076 -0.013 0.010 0.039 -0.026 0.397 0.988 
ASD-1 0.044 0.008 -0.034 -0.075 -0.017 0.008 0.038 -0.025 0.409 0.958 
OCD-0001 -0.066 0.020 -0.006 0.017 0.010 -0.011 0.009 0.152 0.490 0.209 
OCD-001 -0.046 -0.001 0.001 0.005 0.020 -0.007 0.053 0.073 0.856 0.169 
OCD-01 -0.031 -0.041 0.023 -0.010 0.050 0.009 0.071 0.005 0.523 0.0895 
OCD-05 -0.035 -0.017 0.025 0.007 0.023 0.017 0.053 -0.092 0.740 0.453 
OCD-5 -0.038 -0.021 0.021 0.011 -0.001 0.026 0.130 -0.101 0.159 0.137 
OCD-1 -0.033 -0.025 0.022 0.006 -0.002 0.028 0.126 -0.107 0.169 0.157 
INT-0001 0.114 0.101 -0.033 0.057 -0.038 -0.025 -0.038 -0.230 2.17e-4 4.15e-5 
INT-001 0.100 0.112 -0.020 0.025 -0.025 -0.030 -0.086 -0.161 1.88e-3 2.81e-5 
INT-01 0.121 0.118 -0.006 0.030 -0.038 -0.054 -0.113 -0.120 1.61e-4 6.25e-7 
INT-05 0.123 0.116 -0.003 0.078 -0.074 -0.031 -0.136 -0.072 7.19e-6 5.26e-7 
INT-5 0.093 0.113 0.014 0.059 -0.090 -0.027 -0.156 -0.103 1.24e-6 7.46e-8 
INT-1 0.092 0.137 0.016 0.062 -0.089 -0.029 -0.160 -0.097 7.93e-7 5.78e-8 
 
Number of symptoms analysed both as an 8-level factor, denoted by p(fac) and as a quantitative 
variable, denoted by p(quant). Numbers in columns headed by symptom count are the mean PRS 
among individuals with that number of symptoms. 
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Supplementary Table S16: Association of SCZ PRS with symptoms after 
correction for the number of other symptoms present (general severity) 
PRS 
psy dep irb VAB apt POB cog 
SCZ-0001 0.00416 0.234 0.138 0.914 0.458 0.187 0.253 
SCZ-001 0.00370 0.158 0.0662 0.717 0.850 0.0207 0.470 
SCZ-01 0.0157 0.104 0.00293 0.227 0.548 0.0589 0.929 
SCZ-05 0.0383 0.0426 0.000904 0.0644 0.339 0.269 0.975 
SCZ-5 0.0249 0.0844 0.00370 0.189 0.204 0.0432 0.694 
SCZ-1 0.0295 0.0824 0.00419 0.176 0.195 0.0412 0.733 
 
Nominally significant associations shown in bold.  
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
 
 
Supplementary Table S17: Association of MDD PRS with symptoms after 
correction for the number of other symptoms present (general severity) 
PRS 
psy dep irb VAB apt POB cog 
MDD-0001 0.350 0.00369 0.00298 0.0667 0.308 0.193 0.600 
MDD-001 0.113 0.00306 0.0183 0.0234 0.468 0.243 0.318 
MDD-01 0.152 2.41x10-5 0.0589 0.0588 0.885 0.602 0.945 
MDD-05 0.115 3.46x10-4 0.196 0.258 0.759 0.749 0.202 
MDD-5 0.234 9.34x10-4 0.388 0.101 0.909 0.783 0.195 
MDD-1 0.290 5.44x10-4 0.336 0.0906 0.863 0.898 0.246 
 
Nominally significant associations shown in bold.  
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Supplementary Table S18: Association of intelligence PRS with symptoms after 
correction for the number of other symptoms present (general severity) 
PRS 
psy dep irb VAB apt POB cog 
INT-0001 0.179 0.862 0.277 0.110 0.544 0.842 0.036 
INT-001 0.637 0.221 0.701 0.088 0.429 0.729 0.022 
INT-01 0.988 0.848 0.167 0.019 0.570 0.551 0.0078 
INT-05 0.696 0.728 0.149 0.069 0.149 0.654 0.0113 
INT-5 0.553 0.448 0.166 0.044 0.069 0.939 0.0444 
INT-1 0.535 0.487 0.149 0.047 0.065 0.981 0.0476 
 
Nominally significant associations shown in bold. 
dep = depression, irb = irritability, psy = psychosis, apt = apathy, VAB = violent/aggressive behaviour. 
POB= perseverative/obsessive behaviour. cog=cognitive impairment. 
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Guidelines for the age at onset questionnaire for EHDN-HD Registry patients  
This questionnaire will capture essential and detailed information on when signs and symptoms that 
may be related or unrelated to HD first appear. Use the suggested wording below as a guide, but ask 
any other questions you need to try and date the onset as accurately as possible. Ask the patient 
first, then the carer (explain to the carer at the beginning that you will give them a chance to state 
their views after you have first heard from the patient) and finally record your own judgement about 
onset, taking account of what has been said by both patient and carer, and also what you can find in 
the case notes (or any other independent sources of information). It is not uncommon to find a 
record by a genetic counsellor who saw the patient and noticed choreiform movements, or an 
interview with a relative who mentioned that the family think the patient is affected, and this 
information may pre-date the estimates of either the patient or the carer who is acting as your 
informant on this occasion. Use your own judgement about the evidence, but avoid making guesses 
based only on your own experience of how long the average patient would need to be affected to 
reach this stage in the illness.  
1. Motor symptoms:  
 When did you first notice any motor symptoms of HD, such as fidgety movements or 
clumsiness? Can you remember a particular occasion when this happened and you first 
realised you might be developing the family illness? What were you doing at the time? Where 
were you? Did you mention it to anyone else? (Try to identify any landmark events in the 
patient’s life around that time, such as holidays, births, marriages & deaths in the family, etc, 
which might help to anchor the onset date by asking whether the onset was before or after 
that particular landmark)  
2. Depression:  
 Have you ever suffered from depression for a period of 4 weeks or more? Was there ever a 
time you felt so low that you thought about ending it all? Have you been treated with 
antidepressants? When was the first time this happened to you (doesn’t necessarily have to 
have been medicated in the first or any subsequent instance)?  
3. Irritability and aggression:  
 Have there been times when you were irritable, bad tempered or ‘cranky’ for a period of 4 
weeks or more? Have you had difficulty keeping control of your temper? When did this begin? 
If so, how bad was the worst ever episode? Has there been overt aggression? If so when did 
this first occur?  
4. Apathy: 
 Have you noticed any change in your level of motivation? For example, has there ever been a 
period of four weeks or more when you lost interest in things that usually matter to you, or 
could not be bothered with activities you usually enjoy, or needed pushing to get around to 
jobs that need to be done, or spent a lot of time sitting around doing nothing? Did this ever 
happen at a time when you were not also feeling depressed? When did you first notice this 
change?  
 
5. Perseverative or Obsessive/Compulsive behaviours:  
 Have you ever been troubled by recurrent thoughts, fears or mental images that came back 
over and over again, or had urges to do something over and over (e.g. double-checking, 
counting things, or washing your hands repeatedly)? Or perhaps found yourself unable to stop 
thinking about something, so that friends said you were getting it out of proportion, or getting 
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a ‘bee in your bonnet’? If so, how bad was the worst ever episode? When was the first time 
this happened to you?  
 
6. Presence of psychosis:  
 Has the patient ever reported symptoms resembling schizophrenia e.g. paranoid thinking, 
delusions and hearing voices. If so when was the first episode?  
 
7. Cognitive symptoms:  
 Have you ever noticed any problems with your memory, or your ability to concentrate on 
things? Have you found it more difficult than it used to be to organise things, or perhaps 
noticed that it takes longer to get things done nowadays? Has anybody commented on this, or 
maybe criticised your performance at work or when doing chores at home? Can you 
remember the first time this happened? (probe as above and look for evidence such as job 
changes etc. which might suggest early cognitive difficulties)  
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van Paemel, Pascale Ribaï, Christine Verellen-Dumoulin 
Leuven: (Universitair Ziekenhuis Gasthuisberg,): Andrea Boogaerts, Wim Vandenberghe,  Dimphna 
van Reijen 
CZECH REPUBLIC 
Prague (Extrapyramidové centrum, Neurologická klinika, 1. LF UK a VFN): Jiří Klempíř, Veronika 
Majerová, Jan Roth, Irena Stárková 
DENMARK 
Copenhagen (Neurogenetics Clinic, Danish Dementia Research Centre, Rigshospitalet, University of 
Copenhagen): Lena E. Hjermind, Oda Jacobsen, Jørgen E Nielsen, Ida Unmack Larsen, Tua Vinther-
Jensen  
FINLAND 
Turku-Suvituuli (Rehabilitation Centre Suvituuli): Heli Hiivola, Hannele Hyppönen, Kirsti 
Martikainen, Katri Tuuha 
FRANCE 
Ellis et al.  Supplement 
21 
Angers (Centre de référence des maladies neurogénétique- CHU d’Angers): Philippe Allain, 
Dominique Bonneau, Marie Bost, Bénédicte Gohier, Marie-Anne Guérid, Audrey Olivier, Adriana 
Prundean, Clarisse Scherer-Gagou, Christophe Verny 
Bordeaux (Hôpital CHU Pellegrin): Blandine Babiloni, Sabrina Debruxelles, Charlotte Duché, Cyril 
Goizet, Laetitia Jameau, Danielle Lafoucrière, Umberto Spampinato 
Lille-Amiens:  
Lille (CHRU Roger Salengro) : Rekha Barthélémy, Christelle De Bruycker, Maryline Cabaret,  Anne-
Sophie Carette, Eric Decorte  Luc Defebvre, Marie Delliaux, Arnaud Delval, Alain Destee, Kathy 
Dujardin, Marie-Hélène Lemaire, Sylvie Manouvrier, Mireille Peter, Lucie Plomhouse, Bernard 
Sablonnière,  Clémence Simonin, Stéphanie Thibault-Tanchou, Isabelle Vuillaume 
Amiens (CHU Nord) : Marcellin Bellonet, Hassan Berrissoul, Stéphanie Blin, Françoise Courtin, Cécile 
Duru, Véronique Fasquel, Olivier Godefroy, Pierre Krystkowiak, Béatrice Mantaux, Martine Roussel, 
Sandrine Wannepain   
Marseille (Hôpital La Timone) : Jean-Philippe Azulay, Marie Delfini, Alexandre Eusebio, Frédérique 
Fluchere, Laura Mundler 
Strasbourg (Hôpital Civil) : Mathieu Anheim, Celine Julié, Ouhaid Lagha Boukbiza, Nadine Longato, 
Gabrielle Rudolf, Christine Tranchant, Marie-Agathe Zimmermann  
GERMANY 
Aachen (Universitätsklinikum Aachen, Neurologische Klinik): Christoph Michael Kosinski, Eva 
Milkereit, Daniela Probst, Kathrin Reetz, Christian Sass, Johannes  Schiefer, Christiane Schlangen, 
Cornelius J. Werner 
Berlin (Klinik und Poliklinik für Neurologie - Charité - Universitätsmedizin Berlin): Harald 
Gelderblom, Josef Priller, Harald Prüß, Eike Jakob Spruth 
Bochum (Huntington-Zentrum (NRW) Bochum im St. Josef-Hospital): Gisa Ellrichmann, Lennard 
Herrmann, Rainer Hoffmann, Barbara Kaminski, Peter Kotz, Christian Prehn, Carsten Saft 
Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang): Herwig Lange, Robert 
Maiwald 
Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik 
und Poliklinik für Neurologie): Matthias Löhle, Antonia Maass, Simone Schmidt,  Cecile Bosredon, 
Alexander Storch, Annett Wolz, Martin Wolz 
Freiburg (Universitätsklinik Freiburg, Neurologie): Philipp Capetian, Johann Lambeck, Birgit Zucker 
Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie): Kai 
Boelmans, Christos Ganos, Walburgis Heinicke, Ute Hidding, Jan Lewerenz, Alexander Münchau, 
Michael Orth, Jenny Schmalfeld, Lars Stubbe, Simone Zittel 
Hannover (Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule 
Hannover): Gabriele Diercks, Dirk Dressler, Heike Gorzolla, Christoph Schrader, Pawel Tacik 
Itzehoe (Schwerpunktpraxis Huntington, Neurologie und Psychiatrie): Michael Ribbat 
Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd): Bernhard Longinus 
Marburg Uni (Universität Marburg, Neurologie): Katrin Bürk, Jens Carsten Möller, Ida Rissling 
München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der 
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Neurologischen Klinik und Poliklinik der Technischen Universität München): Mark Mühlau, 
Alexander Peinemann, Michael Städtler, Adolf Weindl, Juliane Winkelmann, Cornelia Ziegler 
Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie): Natalie Bechtel, 
Heike Beckmann, Stefan Bohlen, Eva Hölzner, Herwig Lange, Ralf Reilmann, Stefanie Rohm, Silke 
Rumpf , Sigrun Schepers, Natalia Weber  
Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils)): Matthias Dose, Gabriele Leythäuser, 
Ralf Marquard, Tina Raab, Alexandra Wiedemann  
Ulm (Universitätsklinikum Ulm, Neurologie): Katrin Barth, Andrea Buck, Julia Connemann, Daniel 
Ecker, Carolin Geitner, Christine Held, Andrea Kesse, Bernhard Landwehrmeyer, Christina Lang, Jan 
Lewerenz, Franziska Lezius, Solveig Nepper, Anke Niess, Michael Orth, Ariane Schneider, Daniela 
Schwenk, Sigurd Süßmuth, Sonja Trautmann, Patrick Weydt 
ITALY 
Bari Clinica Neurologica - Neurophysiopatology of Pain Unit UNIVERSITA' DI BARI): Claudia Cormio, 
Vittorio Sciruicchio, Claudia Serpino, Marina de Tommaso 
Bologna (DIBINEM - Alma Mater Studiorum - Università di Bologna; IRCCS Istituto delle Scienze 
Neurologiche di Bologna): Sabina Capellari, Pietro Cortelli, Roberto Galassi, Rizzo Giovanni, Roberto 
Poda, Cesa Scaglione 
Florence (Dipartimento di Scienze Neurologiche e Psichiatriche Universita' degli Studi di Firenze-
Azienda Ospedaliera Universitaria Careggi): Elisabetta Bertini, Elena Ghelli, Andrea Ginestroni, 
Francesca Massaro, Claudia Mechi, Marco Paganini, Silvia Piacentini, Silvia Pradella, Anna Maria 
Romoli, Sandro Sorbi 
Genoa (Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-
Infantili, Università di Genova): Giovanni Abbruzzese, Monica Bandettini di Poggio, Giovanna 
Ferrandes, Paola Mandich, Roberta Marchese 
Milan (Fondazione IRCCS Istituto Neurologico Carlo Besta):  
Alberto Albanese, Daniela Di Bella, Anna Castaldo, Stefano Di Donato, Cinzia Gellera, Silvia Genitrini, 
Caterina Mariotti, Daniela Monza, Lorenzo Nanetti, Dominga Paridi, Paola Soliveri, Chiara Tomasello 
Naples (Dipartimento di Neuroscienze, Scienze Riproduttive e Odontostomatologiche, Università 
Federico II): Giuseppe De Michele, Luigi Di Maio, Marco Massarelli, Silvio Peluso, Alessandro Roca, 
Cinzia Valeria Russo, Elena Salvatore, Pierpaolo Sorrentino 
Pozzilli (IS) (Centro di Neurogenetica e Malattie Rare - IRCCS Neuromed): Enrico Amico, Mariagrazia 
Favellato, Annamaria Griguoli, Irene Mazzante, Martina Petrollini, Ferdinando Squitieri and Rome 
(Lega Italiana Ricerca Huntington e malattie correlate - onlus / www.LIRH.it): Barbara D'Alessio, 
Chiara Esposito  
Rome (Istituto di Farmacologia Traslazionale & Istituto di Scienze e Tecnologie della Cognizione 
/CNR,  Istituto di Neurologia Università Cattolica del Sacro Cuore): Anna Rita Bentivoglio, Marina 
Frontali, Arianna Guidubaldi, Tamara Ialongo, Gioia Jacopini, Carla Piano, Silvia Romano, Francesco 
Soleti, Maria Spadaro, Paola Zinzi 
NETHERLANDS 
Enschede (Medisch Spectrum Twente): Monique S.E. van Hout, Marloes E. Verhoeven, Jeroen P.P. 
van Vugt, A. Marit de Weert 
Groningen (Polikliniek Neurologie): J.J.W. Bolwijn, M. Dekker, B. Kremer, K.L. Leenders, J.C.H. van 
Oostrom 
Ellis et al.  Supplement 
23 
Leiden (Leiden University Medical Centre (LUMC)): Simon J. A. van den Bogaard, Reineke Bos, Eve 
M. Dumas, Ellen P. ‘t Hart, Raymund A.C. Roos  
Nijmegen (Universitair Medisch Centrum St. Radboud, Neurology): Berry Kremer, C.C.P. Verstappen 
NORWAY 
Oslo University Hospital (Rikshospitalet, Dept. of Medical Genetics and Dept. of Neurology): Olaf 
Aaserud, Jan Frich C., Arvid Heiberg, Marleen R. van Walsem, Ragnhild Wehus  
Oslo University Hospital (Ulleval, Dept. of Medical Genetics and Dept.of Neurorehabilitation): 
Kathrine Bjørgo, Madeleine Fannemel, Per F. Gørvell, Eirin Lorentzen, Susana Pro Koivisto, Lars 
Retterstøl, Bodil Stokke 
Trondheim (St. Olavs Hospital): Inga Bjørnevoll, Sigrid Botne Sando 
POLAND 
Gdansk (St. Adalbert Hospital, Gdansk, Medical University of Gdansk, Neurological and Psychiatric 
Nursing Dpt.): Artur Dziadkiewicz, Malgorzata Nowak, Piotr Robowski, Emilia Sitek, Jaroslaw Slawek, 
Witold Soltan, Michal Szinwelski 
Katowice (Medical University of Silesia, Katowice): Magdalena Blaszcyk, Magdalena Boczarska-
Jedynak, Ewelina Ciach-Wysocka, Agnieszka Gorzkowska, Barbara Jasinska-Myga, Gabriela 
Kłodowska–Duda, Gregorz Opala, Daniel Stompel  
Krakow (Krakowska Akademia Neurologii): Krzysztof Banaszkiewicz, Dorota Boćwińska, Kamila 
Bojakowska-Jaremek, Małgorzata Dec, Malgorzata Krawczyk, Monika Rudzińska, Elżbieta Szczygieł, 
Andrzej Szczudlik, Anna Wasielewska, Magdalena Wójcik  
Poznan (Poznan University of Medical Sciences, Poland): Anna Bryl, Anna Ciesielska, Aneta 
Klimberg, Jerzy Marcinkowski, Husam Samara, Justyna Sempołowicz, Daniel Zielonka 
Warsaw-MU (Medical University of Warsaw, Neurology): Anna Gogol (formerly Kalbarczyk), Piotr 
Janik, Hubert Kwiecinski, Zygmunt Jamrozik 
Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, First Dep. of Neurology): 
Jakub Antczak, Katarzyna Jachinska, Wioletta Krysa, Maryla Rakowicz, Przemyslaw Richter, Rafal 
Rola, Danuta Ryglewicz, Halina Sienkiewicz-Jarosz, Iwona Stępniak, Anna Sułek, Grzegorz Witkowski, 
Jacek Zaremba, Elzbieta Zdzienicka, Karolina Zieora-Jakutowicz 
PORTUGAL 
Coimbra (Hospital Universitário de Coimbra): Cristina Januário, Filipa Júlio 
Lisbon (Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, 
University of Lisbon): Joaquim J Ferreira, Miguel Coelho, Leonor Correia Guedes, Tiago Mendes, 
Tiago Mestre, Anabela Valadas 
Porto (Hospital de São João, (Faculdade de Medicina da Universidade do Porto)): Carlos Andrade, 
Miguel Gago, Carolina Garrett, Maria Rosália Guerra. 
SPAIN 
Badajoz (Hospital Infanta Cristina): Carmen Durán Herrera, Patrocinio Moreno Garcia 
Barcelona-Hospital Mútua de Terrassa: Miquel Aguilar Barbera, Dolors Badenes Guia, Laura Casas 
Hernanz , Judit López Catena, Pilar Quiléz Ferrer, Ana Rojo Sebastián, Gemma Tome Carruesco 
Barcelona-Bellvitge (Hospital Universitari de Bellvitge): Jordi Bas, Núria Busquets, Matilde Calopa 
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Barcelona-Merced (Hospital Mare de Deu de La Merced): Misericordia Floriach Robert, Celia 
Mareca Viladrich, Jesús Miguel Ruiz Idiago, Antonio Villa Riballo 
Burgos (Servicio de Neurología Hospital General Yagüe): Esther Cubo, Cecilia Gil Polo, Natividad 
Mariscal Perez, Jessica Rivadeneyra 
Granada (Hospital Universitario San Cecilio, Neurología): Francisco Barrero, Blas Morales  
Madrid-Clinico (Hospital Clínico Universitario San Carlos): María Fenollar, Rocío García-Ramos 
García, Paloma Ortega, Clara Villanueva  
Madrid RYC (Hospital Ramón y Cajal, Neurología): Javier Alegre, Mónica Bascuñana, Juan Garcia 
Caldentey, Marta Fatás Ventura, Guillermo García Ribas, Justo García de Yébenes, José Luis López-
Sendón Moreno, Patricia Trigo Cubillo  
Madrid FJD (Madrid-Fundación Jiménez Díaz): Javier Alegre, Fernando Alonso Frech, Justo García de 
Yébenes, Pedro J García Ruíz, Asunción Martínez-Descals, Rosa Guerrero, María José Saiz Artiga, 
Vicenta Sánchez  
Murcia (Hospital Universitario Virgen de la Arrixaca): María Fuensanta Noguera Perea, Lorenza 
Fortuna, Salvadora Manzanares, Gema Reinante, María Martirio Antequera Torres, Laura Vivancos 
Moreau  
Oviedo (Hospital Central de Asturias): Sonia González González, Luis Menéndez Guisasola, Carlos 
Salvador, Esther Suaréz San Martín 
Palma de Mallorca (Hospital Universitario Son Espases): Inés Legarda Ramirez, Aranzazú Gorospe, 
Mónica Rodriguez Lopera, Penelope Navas Arques, María José Torres Rodríguez, Barbara Vives 
Pastor 
Pamplona (Complejo Hospitalario de Navarra): Itziar Gaston, Maria Dolores Martinez-Jaurrieta, 
Maria A. Ramos-Arroyo  
Sevilla ("Hospital Virgen Macarena"): Jose Manuel Garcia Moreno, Carolina Mendez Lucena, Fatima 
Damas Hermoso, Eva Pacheco Cortegana, José Chacón Peña, Luis Redondo 
Sevilla (Hospital Universitario Virgen del Rocío): Fátima Carrillo, María Teresa Cáceres, Pablo Mir, 
María José Lama Suarez, Laura Vargas-González 
Valencia (Hospital la Fe): Maria E. Bosca, Francisco Castera Brugada, Juan Andres Burguera, Anabel 
Campos Garcia, Carmen Peiró Vilaplana 
SWEDEN 
Göteborg (Sahlgrenska University Hospital): Peter Berglund, Radu Constantinescu, Gunnel Fredlund, 
Ulrika Høsterey-Ugander, Petra Linnsand, Liselotte Neleborn-Lingefjärd, Jan Wahlström, Magnus 
Wentzel 
Umeå (Umeå University Hospital): Ghada Loutfi, Carina Olofsson, Eva-Lena Stattin, Laila Westman, 
Birgitta Wikström  
SWITZERLAND 
Bern: Jean-Marc Burgunder, Yanik Stebler (Swiss HD Zentrum), Alain Kaelin, Irene Romero, Michael 
Schüpbach, Sabine Weber Zaugg (Zentrum für Bewegungsstörungen, Neurologische Klinik und 
Poliklinik, Universität Bern) 
Zürich (Department of Neurology, University Hospital Zürich): Maria Hauer, Roman Gonzenbach, 
Hans H. Jung, Violeta Mihaylova, Jens Petersen 
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UNITED KINGDOM 
Aberdeen (NHS Grampian Clinical Genetics Centre & University of Aberdeen): Roisin Jack, Kirsty 
Matheson, Zosia Miedzybrodzka, Daniela Rae, Sheila A Simpson, Fiona Summers, Alexandra Ure, 
Vivien Vaughan    
Birmingham (The Barberry Centre, Dept of Psychiatry): Shahbana Akhtar, Jenny Crooks, Adrienne 
Curtis, Jenny de Souza (Keylock), John Piedad, Hugh Rickards, Jan Wright 
Bristol (North Bristol NHS Trust, Southmead hospital): Elizabeth Coulthard, Louise Gethin, Beverley 
Hayward, Kasia Sieradzan, Abigail Wright  
Cambridge (Cambridge Centre for Brain Repair, Forvie Site): Matthew Armstrong, Roger A. Barker, 
Deidre O’Keefe, Anna Di Pietro, Kate Fisher, Anna Goodman, Susan Hill, Ann Kershaw, Sarah Mason, 
Nicole Paterson, Lucy Raymond, Rachel Swain, Natalie Valle Guzman 
Cardiff (Schools of Medicine and Biosciences, Cardiff University): Monica Busse, Cynthia Butcher, 
Jenny Callaghan, Stephen Dunnett, Catherine Clenaghan, Ruth Fullam, Olivia Handley, Sarah Hunt, 
Lesley Jones, Una Jones, Hanan Khalil, Sara Minster, Michael Owen, Kathleen Price, Anne Rosser, 
Jenny Townhill  
Edinburgh (Molecular Medicine Centre, Western General Hospital, Department of Clinical 
Genetics):  Maureen Edwards, Carrie Ho (Scottish Huntington´s Association), Teresa Hughes (Scottish 
Huntington´s Association), Marie McGill, Pauline Pearson, Mary Porteous, Paul Smith (Scottish 
Huntington´s Association) 
Fife (Scottish Huntington's Association Whyteman's Brae Hospital): Peter Brockie, Jillian Foster, 
Nicola Johns, Sue McKenzie, Jean Rothery, Gareth Thomas, Shona Yates 
Gloucester (Department of Neurology Gloucestershire Royal Hospital): Liz Burrows, Carol Chu, Amy 
Fletcher, Deena Gallantrae, Stephanie Hamer, Alison Harding, Stefan Klöppel, Alison Kraus, Fiona 
Laver, Monica Lewis, Mandy Longthorpe, Ivana Markova, Ashok Raman, Nicola Robertson, Mark 
Silva, Aileen Thomson, Sue Wild, Pam Yardumian  
Hull (Castle Hill Hospital): Carol Chu, Carole Evans, Deena Gallentrae, Stephanie Hamer, Alison 
Kraus, Ivana Markova, Ashok Raman 
Leeds (Chapel Allerton Hospital, Department of Clinical Genetics): Leeds (Chapel Allerton Hospital, 
Clinical Genetics): Carol Chu, Stephanie Hamer, Emma Hobson, Stuart Jamieson, Alison Kraus, Ivana 
Markova, Ashok Raman, Hannah Musgrave, Liz Rowett, Jean Toscano, Sue Wild, Pam Yardumian  
Leicester (Leicestershire Partnership Trust, Mill Lodge): Colin Bourne, Jackie Clapton, Carole 
Clayton, Heather Dipple, Dawn Freire-Patino, Janet Grant, Diana Gross, Caroline Hallam, Julia 
Middleton, Ann Murch, Catherine Thompson  
Liverpool (Walton Centre for Neurology and Neurosurgery): Sundus Alusi, Rhys Davies, Kevin Foy, 
Emily Gerrans, Louise Pate  
London (Guy's Hospital): Thomasin Andrews, Andrew Dougherty, Charlotte Golding, Fred Kavalier, 
Hana Laing, Alison Lashwood, Dene Robertson, Deborah Ruddy, Alastair Santhouse, Anna Whaite  
London (The National Hospital for Neurology and Neurosurgery): Thomasin Andrews, Stefania 
Bruno, Karen Doherty, Charlotte Golding, Salman Haider, Davina Hensman, Nayana Lahiri, Monica 
Lewis, Marianne Novak, Aakta Patel, Nicola Robertson, Elisabeth Rosser, Sarah Tabrizi, Rachel Taylor, 
Thomas Warner, Edward Wild 
Manchester (Genetic Medicine, University of Manchester, Manchester Academic Health Sciences 
Centre and Central Manchester University Hospitals NHS Foundation Trust): Natalie Arran, Judith 
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Bek, Jenny Callaghan, David Craufurd, Ruth Fullam, Marianne Hare, Liz Howard, Susan Huson, Liz 
Johnson, Mary Jones, Helen Murphy, Emma Oughton, Lucy Partington-Jones, Dawn Rogers, Andrea 
Sollom, Julie Snowden, Cheryl Stopford, Jennifer Thompson, Iris Trender-Gerhard, Nichola 
Verstraelen (formerly Ritchie), Leann Westmoreland 
Oxford (Oxford University Hospitals NHS Trust, Dept. of Neurosciences, University of Oxford): 
Richard Armstrong, Kathryn Dixon, Andrea H Nemeth, Gill Siuda, Ruth Valentine 
Plymouth (Plymouth Huntington Disease Service, Mount Gould Hospital): David Harrison, Max 
Hughes, Andrew Parkinson, Beverley Soltysiak 
Sheffield (The Royal Hallamshire Hospital– Sheffield Children’s Hospital): Oliver Bandmann, Alyson 
Bradbury, Paul Gill, Helen Fairtlough, Kay Fillingham, Isabella Foustanos, Mbombe Kazoka, Kirsty 
O’Donovan, Nadia Peppa, Cat Taylor, Katherine Tidswell, Oliver Quarrell 
EHDN’s associate site in Singapore: National Neuroscience Institute Singapore: Jean-Marc 
Burgunder, Puay Ngoh Lau, Emmanul Pica, Louis Tan 
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